Altaris Capital Partners acquires chemicals firm Johnson Matthey’s health unit in $433m deal

Johnson Matthey said on Friday it will sell its health business to investment firm Altaris Capital Partners for an enterprise value of about $432.71m, as the chemicals maker plans to refocus on its core assets.

The London-listed company said it would retain a 30% stake in the health business, which develops and manufactures specialist and complex active pharmaceutical ingredients.

Johnson Matthey, which began a review of the division eight months ago, said it would take an impairment hit of 200 million pounds from the sale expected to close by mid-2022.

Get the week’s top news delivered directly to your inbox – Sign up for our newsletter

Sign up

The news comes after the firm announced last month that it was selling its battery materials and glass technologies businesses, while it brings in Bayer AG’s Liam Condon as its new boss in March.

The British company, which makes car pollution filters and plans to focus on areas such as hydrogen technologies, said it would redeploy about 150 million pounds of capital expenditure previously earmarked for the non-core health division to higher growth businesses.

Source: Reuters

Can’t stop reading? Read more